Article
Article
Gurzau Diana
https://rpubs.com/alex_istrate/
0.1 Methods
0.1.1 Statisitcal analysis of the data
To describe the quantitative variables, we used histograms and we calculated the arithmetic means ±standard deviation (SD) [with 95% confidence interval (CI)], as well as the extreme and median values. For the qualitative variables, we used pie or bar charts and calculated the absolute and percentual frequencies of the formed categories.
To study the relationships between quantitative and qualitative variables, we used the T or Mann-Whitney (MW) tests if they were binary, respectively ANOVA or Kruskal-Wallis (KW) if they had more categories. We presented the p values generated by these tests as well as the means ±SD of the groups and the difference of the means with associated 95% CI. We graphically presented the results in the form of box plots. To study the relationships between the quantitative variables we used the Spearman correlation coefficient (R), with the associated p-value and graphically presented the relations as scatter plots, on which we added the regression line. To describe the relationships between the qualitative variables we used the Chi² or Fisher test and the Cramer phi or V and Odds-Ratio (OR) / Relative Risk (RR) indicators with 95% CI. We graphically presented the results in the form of pie or bar charts.
We used WPS Office 2019 for database management. For all statistical analyzes and subsequent graphs we used R 4.0.0 [1]. We considered p <0.05 to be statistically significant and p <0.10 to show only a tendency towards statistical significance.
0.2 Results
- BRS-ul la femei este mai frecvent asociat cu cardiopatie microvasculara (coro normale) comparativ cu pacientii de sex masculin
Pare sa fie, dar nu destul cat sa se numeasca semnificativ statistic. Un OR de 2, cu CI95% inferioara de 0.7 sugereaza asta, dar iti trebuie lot mai mare (2.5x mai mare).
coro normale ~ Sex [toti au brs]
Variable | Details | F | M | Total | Statistics |
Sex | 35 (50.0%) | 35 (50.0%) | 70 | ||
Normal coronaries | 28 (80.0%) | 23 (65.7%) | 51 (72.9%) | OR=2.09 [0.71, 6.16] (p=0.282) | |
OR = odds-ratio [95% CI] and p value from Fisher test); | |||||
- Daca exista o corelatie intre dimensiunea, largimea qrs-ului si afectarea coronariana macrovasculara (nr de leziuni)
Nu prea
QRS (ms) ~ Coronary lessions [columns+SD]
Subset | N | Mean ±SD | Med (min:max) |
QRS (ms) (Shapiro-Wilk normality test: p<0.001) | |||
(total) | 70 (100.0%) | 134.714 ±8.96 | 130.00 (120.00:160.0) |
Coronary lessions (Wilcoxon rank sum test with continuity correction: p=0.675) | |||
yes | 19 (27.1%) | 133.684 ±6.84 | 130.00 (120.00:150.0) |
no | 51 (72.9%) | 135.098 ±9.67 | 130.00 (120.00:160.0) |
Coronary lessions4 (Kruskal-Wallis rank sum test: p=0.415) | |||
none | 51 (72.9%) | 135.098 ±9.67 | 130.00 (120.00:160.0) |
univascular | 9 (12.9%) | 132.222 ±6.67 | 130.00 (130.00:150.0) |
bivascular | 5 (7.1%) | 132.000 ±8.37 | 130.00 (120.00:140.0) |
trivascular | 5 (7.1%) | 138.000 ±4.47 | 140.00 (130.00:140.0) |
- Care sunt factorii care determina mai frecvent angina microvasculara la femeile cu brs
Cred ca nimic. am gasit ESR <, IVS size <, si niste doze de tratament. Nu stiu cum te descurci cu cauzalitatea.
Sex:F, coro normale ~ .
Variable | Details | yes | no | Total | Statistics |
Normal coronaries | 28 (80.0%) | 7 (20.0%) | 35 | ||
Sex | F | 28 (100%) | 7 (100%) | 35 (100%) | OR=3.80 [0.07, 207.81] (p>0.999) |
M | 0 | 0 | 0 | ||
Age | M (min:max) | 66 (47:88) | 70 (58:76) | 66 (47:88) | T-test: p=0.259 |
μ ±SD | 64.61 ±8.96 | 68.71 ±5.74 | 65.43 ±8.51 | ||
LBBB type | new | 7 (25.0%) | 5 (71.4%) | 12 (34.3%) | V=0.39 (p=0.067) |
permanent | 20 (71.4%) | 2 (28.6%) | 22 (62.9%) | ||
intermittent | 1 (3.6%) | 0 | 1 (2.9%) | ||
alternating | 0 | 0 | 0 | ||
QRS (ms) | M (min:max) | 130 (120:160) | 130 (130:150) | 130 (120:160) | MW: p=0.469 |
μ ±SD | 132.14 ±9.57 | 134.29 ±7.87 | 132.57 ±9.19 | ||
Uric acid | M (min:max) | 6.34 (2.78:9.95) | 6.21 (4.67:9.7) | 6.32 (2.78:9.95) | T-test: p=0.364 |
μ ±SD | 6.30 ±1.67 | 6.95 ±1.75 | 6.43 ±1.68 | ||
Heart rate | M (min:max) | 70 (55:120) | 70 (60:110) | 70 (55:120) | MW: p=0.934 |
μ ±SD | 72.36 ±14.7 | 74.57 ±16.4 | 72.80 ±14.8 | ||
SBP at admission | M (min:max) | 130 (110:190) | 120 (120:160) | 130 (110:190) | MW: p=0.750 |
μ ±SD | 132.32 ±17.0 | 131.43 ±16.8 | 132.14 ±16.7 | ||
DBP at admission | M (min:max) | 75 (60:100) | 80 (70:90) | 80 (60:100) | MW: p=0.898 |
μ ±SD | 77.50 ±13.2 | 77.14 ±7.56 | 77.43 ±12.2 | ||
Coronarography indication: angina | 24 (85.7%) | 7 (100%) | 31 (88.6%) | OR=0.36 [0.02, 7.54] (p=0.562) | |
Coronarography indication: CMD | 11 (39.3%) | 1 (14.3%) | 12 (34.3%) | OR=3.88 [0.41, 36.79] (p=0.380) | |
CRT indication | 8 (28.6%) | 1 (14.3%) | 9 (25.7%) | OR=2.40 [0.25, 23.24] (p=0.648) | |
CRT implanted | 1 (3.6%) | 1 (14.3%) | 2 (5.7%) | OR=0.22 [0.01, 4.08] (p=0.365) | |
Dominant coronary | right | 21 (75.0%) | 7 (100%) | 28 (80.0%) | OR=0.19 [0.01, 3.77] (p=0.301) |
left | 7 (25.0%) | 0 | 7 (20.0%) | ||
Coronary lessions | 0 | 7 (100%) | 7 (20.0%) | OR=0.00 [0.00, 0.06] (p<0.001) | |
Coronary lessions4 | none | 28 (100%) | 0 | 28 (80.0%) | V=>0.99 (p<0.001) |
univascular | 0 | 3 (42.9%) | 3 (8.6%) | ||
bivascular | 0 | 2 (28.6%) | 2 (5.7%) | ||
trivascular | 0 | 2 (28.6%) | 2 (5.7%) | ||
Stentation | 0 | 3 (42.9%) | 3 (8.6%) | OR=0.02 [0.00, 0.51] (p=0.005) | |
Coronary lessions treatment | surgery | 0 (NA) | 2 (50.0%) | 2 (50.0%) | OR=1.00 [0.01, 73.26] (p>0.999) |
conservative | 0 (NA) | 2 (50.0%) | 2 (50.0%) | ||
abord_coro | femoral | 1 (3.6%) | 0 | 1 (2.9%) | OR=0.82 [0.03, 22.20] (p>0.999) |
radial | 27 (96.4%) | 7 (100%) | 34 (97.1%) | ||
Typical angina | 24 (85.7%) | 6 (85.7%) | 30 (85.7%) | OR=1.00 [0.09, 10.66] (p>0.999) | |
Atypical pain | 3 (10.7%) | 1 (14.3%) | 4 (11.4%) | OR=0.72 [0.06, 8.20] (p>0.999) | |
Smoking | 9 (32.1%) | 1 (14.3%) | 10 (28.6%) | OR=2.84 [0.30, 27.25] (p=0.644) | |
Total cholesterol | M (min:max) | 183.5 (111:268) | 194 (124:240) | 189 (111:268) | T-test: p=0.848 |
μ ±SD | 181.61 ±44.0 | 185.14 ±39.7 | 182.31 ±42.6 | ||
LDL cholesterol | M (min:max) | 101.5 (45:164) | 113 (64:168) | 108 (45:168) | T-test: p=0.733 |
μ ±SD | 105.39 ±33.8 | 110.29 ±33.2 | 106.37 ±33.2 | ||
HDL cholesterol | M (min:max) | 42 (25:57) | 39 (28:50) | 42 (25:57) | T-test: p=0.325 |
μ ±SD | 41.61 ±7.97 | 38.29 ±7.41 | 40.94 ±7.87 | ||
Tryglicerides | M (min:max) | 160.5 (60:472) | 187 (95:287) | 161 (60:472) | MW: p=0.621 |
μ ±SD | 166.04 ±78.8 | 177.71 ±74.0 | 168.37 ±77.0 | ||
Glicaemia (mg/dl) | M (min:max) | 103.5 (85:247) | 115 (90:168) | 109 (85:247) | MW: p=0.665 |
μ ±SD | 121.86 ±44.2 | 120.14 ±27.5 | 121.51 ±41.1 | ||
ESR | M (min:max) | 14 (4:34) | 26 (10:40) | 16 (4:40) | MW: p=0.008 |
μ ±SD | 16.11 ±7.96 | 28.43 ±10.2 | 18.57 ±9.67 | ||
TSH | M (min:max) | 1.42 (0.23:4.02) | 1.32 (0.64:2.69) | 1.41 (0.23:4.02) | MW: p=0.825 |
μ ±SD | 1.63 ±0.956 | 1.58 ±0.705 | 1.62 ±0.903 | ||
Troponin | reacted | 1 (14.3%) | 0 | 1 (7.7%) | OR=3.00 [0.10, 88.13] (p>0.999) |
not reacted | 6 (85.7%) | 6 (100%) | 12 (92.3%) | ||
NT-proBNP | 5 (17.9%) | 1 (14.3%) | 6 (17.1%) | OR=1.30 [0.13, 13.37] (p>0.999) | |
NT-proBNP (pg/ml) | M (min:max) | 1680 (300:7735) | 2648 (2648:2648) | 2164 (300:7735) | MW: p>0.999 |
μ ±SD | 2733.80 ±2989.9 | 2648.00 ±NA | 2719.50 ±2674.5 | ||
LVEF % | M (min:max) | 48.5 (30:55) | 45 (30:68) | 47 (30:68) | MW: p=0.779 |
μ ±SD | 43.29 ±8.17 | 46.14 ±11.9 | 43.86 ±8.9 | ||
Kinetics abnormalities | 15 (53.6%) | 5 (71.4%) | 20 (57.1%) | OR=0.46 [0.08, 2.79] (p=0.672) | |
IVS dissynchronism | 26 (92.9%) | 7 (100%) | 33 (94.3%) | OR=0.71 [0.03, 16.37] (p>0.999) | |
IVS size (mm) | M (min:max) | 12 (9:15) | 14 (11:15) | 12 (9:15) | MW: p=0.014 |
μ ±SD | 11.54 ±1.5 | 13.29 ±1.38 | 11.89 ±1.62 | ||
Systolic LV diameter (mm) | M (min:max) | 52 (38:67) | 50 (44:70) | 52 (38:70) | T-test: p=0.521 |
μ ±SD | 54.21 ±7.83 | 52.00 ±9.07 | 53.77 ±8.0 | ||
Diastolic LV diameter (mm) | M (min:max) | 36.5 (23:58) | 32 (25:60) | 36 (23:60) | MW: p=0.432 |
μ ±SD | 38.43 ±10.2 | 35.86 ±12.0 | 37.91 ±10.5 | ||
Diastolic disfunction | 27 (96.4%) | 7 (100%) | 34 (97.1%) | OR=1.22 [0.05, 33.17] (p>0.999) | |
Diastolic disfunction4 | none | 1 (3.6%) | 0 | 1 (2.9%) | V=0.29 (p=0.387) |
mild | 20 (71.4%) | 6 (85.7%) | 26 (74.3%) | ||
moderate | 6 (21.4%) | 0 | 6 (17.1%) | ||
severe | 1 (3.6%) | 1 (14.3%) | 2 (5.7%) | ||
HBP | 25 (89.3%) | 6 (85.7%) | 31 (88.6%) | OR=1.39 [0.12, 15.81] (p>0.999) | |
HBP4 | none | 3 (10.7%) | 1 (14.3%) | 4 (11.4%) | V=0.16 (p=0.838) |
I | 1 (3.6%) | 0 | 1 (2.9%) | ||
II | 12 (42.9%) | 2 (28.6%) | 14 (40.0%) | ||
III | 12 (42.9%) | 4 (57.1%) | 16 (45.7%) | ||
DM | 11 (39.3%) | 4 (57.1%) | 15 (42.9%) | OR=0.49 [0.09, 2.60] (p=0.430) | |
NYHA | II | 7 (38.9%) | 2 (40.0%) | 9 (39.1%) | OR=0.95 [0.13, 7.23] (p>0.999) |
III | 11 (61.1%) | 3 (60.0%) | 14 (60.9%) | ||
Atrial fibrilation | 5 (17.9%) | 3 (42.9%) | 8 (22.9%) | OR=0.29 [0.05, 1.72] (p=0.312) | |
Obesity | 23 (82.1%) | 5 (71.4%) | 28 (80.0%) | OR=1.84 [0.27, 12.35] (p=0.608) | |
Other comorbidities | 18 (64.3%) | 3 (42.9%) | 21 (60.0%) | OR=2.40 [0.45, 12.94] (p=0.401) | |
Oral antidiabetics | 5 (17.9%) | 2 (28.6%) | 7 (20.0%) | OR=0.54 [0.08, 3.65] (p=0.608) | |
Insulin | 3 (10.7%) | 2 (28.6%) | 5 (14.3%) | OR=0.30 [0.04, 2.29] (p=0.256) | |
ICC/IVS | 18 (64.3%) | 5 (71.4%) | 23 (65.7%) | OR=0.72 [0.12, 4.41] (p>0.999) | |
Arrhythmia | 20 (71.4%) | 6 (85.7%) | 26 (74.3%) | OR=0.42 [0.04, 4.03] (p=0.648) | |
Arrhythmia type | supra-ventricular extrasystole | 4 (26.7%) | 2 (50.0%) | 6 (31.6%) | V=0.27 (p=0.509) |
ventricular extrasystole | 8 (53.3%) | 2 (50.0%) | 10 (52.6%) | ||
focal atrial tachycardia | 0 | 0 | 0 | ||
TVNS | 3 (20.0%) | 0 | 3 (15.8%) | ||
Antiarrhythmic medication | 7 (25.9%) | 1 (14.3%) | 8 (23.5%) | OR=2.10 [0.21, 20.64] (p>0.999) | |
Antiarrhythmic drug | amiodarona | 6 (100%) | 1 (100%) | 7 (100%) | OR=4.33 [0.06, 320.40] (p>0.999) |
propafenona | 0 | 0 | 0 | ||
Anticoagulant medication | 5 (17.9%) | 3 (42.9%) | 8 (22.9%) | OR=0.29 [0.05, 1.72] (p=0.312) | |
Antiplatelet medication | 20 (71.4%) | 6 (85.7%) | 26 (74.3%) | OR=0.42 [0.04, 4.03] (p=0.648) | |
Antiplatelet dosage | M (min:max) | 75 (75:75) | 100 (75:150) | 75 (75:150) | MW: p<0.001 |
μ ±SD | 75.00 ±0.0 | 108.33 ±34.2 | 82.69 ±20.9 | ||
Beta-blockers | 27 (96.4%) | 7 (100%) | 34 (97.1%) | OR=1.22 [0.05, 33.17] (p>0.999) | |
Beta-blocker | metoprolol | 10 (37.0%) | 6 (85.7%) | 16 (47.1%) | V=0.40 (p=0.141) |
bisoprolol | 11 (40.7%) | 1 (14.3%) | 12 (35.3%) | ||
nebivolol | 3 (11.1%) | 0 | 3 (8.8%) | ||
carvedilol | 3 (11.1%) | 0 | 3 (8.8%) | ||
Beta-blocker dosage | M (min:max) | 10 (2.5:100) | 100 (10:100) | 25 (2.5:100) | MW: p=0.035 |
μ ±SD | 35.44 ±39.7 | 69.29 ±40.0 | 42.41 ±41.6 | ||
ACE inhibitors / sartans | 26 (96.3%) | 7 (100%) | 33 (97.1%) | OR=1.18 [0.04, 31.99] (p>0.999) | |
ACE inhibitor | prestarium | 15 (100%) | 4 (100%) | 19 (100%) | OR=3.44 [0.06, 199.29] (p>0.999) |
ramipril | 0 | 0 | 0 | ||
Sartan | candesartan | 6 (54.5%) | 2 (66.7%) | 8 (57.1%) | V=0.39 (p=0.548) |
olmesartan | 2 (18.2%) | 0 | 2 (14.3%) | ||
telminsartan | 1 (9.1%) | 1 (33.3%) | 2 (14.3%) | ||
valsartan | 2 (18.2%) | 0 | 2 (14.3%) | ||
ACE inhibitor dosage | M (min:max) | 5 (2.5:10) | 7.5 (5:10) | 5 (2.5:10) | MW: p=0.127 |
μ ±SD | 5.43 ±1.97 | 7.50 ±2.89 | 5.87 ±2.27 | ||
Sartan dosage | M (min:max) | 26 (8:160) | 16 (8:80) | 26 (8:160) | MW: p=0.635 |
μ ±SD | 37.45 ±42.0 | 34.67 ±39.5 | 36.86 ±39.9 | ||
Statins | 20 (71.4%) | 6 (85.7%) | 26 (74.3%) | OR=0.42 [0.04, 4.03] (p=0.648) | |
Statin | atorvastatina | 14 (70.0%) | 5 (83.3%) | 19 (73.1%) | V=0.13 (p=0.518) |
rosuvastatina | 6 (30.0%) | 1 (16.7%) | 7 (26.9%) | ||
simvastatina | 0 | 0 | 0 | ||
Statin dosage | M (min:max) | 10 (5:20) | 15 (10:40) | 10 (5:40) | MW: p=0.563 |
μ ±SD | 14.25 ±5.45 | 18.33 ±11.7 | 15.19 ±7.28 | ||
Diuretics | 21 (75.0%) | 5 (71.4%) | 26 (74.3%) | OR=1.20 [0.19, 7.63] (p>0.999) | |
Diuretic | ansa | 3 (14.3%) | 1 (20.0%) | 4 (15.4%) | V=0.07 (p=0.944) |
ansa/economisitorK | 14 (66.7%) | 3 (60.0%) | 17 (65.4%) | ||
tiazidic | 4 (19.0%) | 1 (20.0%) | 5 (19.2%) | ||
Other anti-ischaemic medication | 17 (60.7%) | 6 (85.7%) | 23 (65.7%) | OR=0.26 [0.03, 2.44] (p=0.380) | |
Nitrates | 15 (53.6%) | 6 (85.7%) | 21 (60.0%) | OR=0.19 [0.02, 1.81] (p=0.203) | |
Trimetazidine | 4 (14.3%) | 0 | 4 (11.4%) | OR=2.76 [0.13, 57.26] (p=0.562) | |
Ca channel blockers | 11 (39.3%) | 4 (57.1%) | 15 (42.9%) | OR=0.49 [0.09, 2.60] (p=0.430) | |
Digoxin | 4 (14.3%) | 2 (28.6%) | 6 (17.1%) | OR=0.42 [0.06, 2.93] (p=0.576) | |
μ ±SD = Mean (standard deviation); M (min:max) = Median (min:max); MW = Mann-Whitney Test; Welch = Welch T-Test (not assuming equal variances); OR/RR = odds-ratio / risk-ratio [95% CI] and p value from Fisher test); V = Cramér V (p value from Chi² test); | |||||
- Indicatia de coronarografie la pacientii cu BRS este mai frecvent facuta la barbati, atat pt angina cat si pentru stabilirea etiologiei cardiomiopatiei dilatative
Coronarography indication: angina -> da Coronarography indication: CMD -> probabil nu
~ Sex
Variable | Details | F | M | Total | Statistics |
Sex | 35 (50.0%) | 35 (50.0%) | 70 | ||
Coronarography indication: angina | 31 (88.6%) | 22 (62.9%) | 53 (75.7%) | OR=4.58 [1.32, 15.93] (p=0.024) | |
Coronarography indication: CMD | 12 (34.3%) | 18 (51.4%) | 30 (42.9%) | OR=0.49 [0.19, 1.29] (p=0.227) | |
OR = odds-ratio [95% CI] and p value from Fisher test); | |||||
- Stabilirea daca BRS-ul asociat cu o FC <125/min este asociat cu boala ischemica.
Nu
Heart rate ~ Coronary lessions, Coronary lessions4, Typical angina, Other anti-ischaemic medication, Nitrates
Variable | >125 bpm | 0-125 bmp | Total | Statistics |
Heart rate | 1 (1.4%) | 69 (98.6%) | 70 | |
Coronary lessions | 0 | 19 (27.5%) | 19 (27.1%) | OR=0.86 [0.03, 22.11] (p>0.999) |
Typical angina | 0 | 52 (75.4%) | 52 (74.3%) | OR=0.11 [0.00, 2.85] (p=0.257) |
Other anti-ischaemic medication | 0 | 38 (55.1%) | 38 (54.3%) | OR=0.27 [0.01, 6.93] (p=0.457) |
Nitrates | 0 | 35 (50.7%) | 35 (50.0%) | OR=0.32 [0.01, 8.23] (p>0.999) |
OR = odds-ratio [95% CI] and p value from Fisher test); | ||||
Variable | [0,71] | (71,Inf] | Total | Statistics |
Heart rate | 35 (50.0%) | 35 (50.0%) | 70 | |
Coronary lessions | 9 (25.7%) | 10 (28.6%) | 19 (27.1%) | OR=0.87 [0.30, 2.48] (p>0.999) |
Typical angina | 28 (80.0%) | 24 (68.6%) | 52 (74.3%) | OR=1.83 [0.61, 5.47] (p=0.413) |
Other anti-ischaemic medication | 21 (60.0%) | 17 (48.6%) | 38 (54.3%) | OR=1.59 [0.62, 4.09] (p=0.472) |
Nitrates | 19 (54.3%) | 16 (45.7%) | 35 (50.0%) | OR=1.41 [0.55, 3.61] (p=0.633) |
OR = odds-ratio [95% CI] and p value from Fisher test); | ||||
Subset | N | Mean ±SD | Med (min:max) |
Heart rate (Shapiro-Wilk normality test: p<0.001) | |||
(total) | 70 (100.0%) | 73.500 ±15.72 | 71.00 (50.00:145.0) |
Coronary lessions (Wilcoxon rank sum test with continuity correction: p=0.643) | |||
yes | 19 (27.1%) | 74.368 ±13.39 | 72.00 (55.00:110.0) |
no | 51 (72.9%) | 73.176 ±16.61 | 70.00 (50.00:145.0) |
Coronary lessions4 (Kruskal-Wallis rank sum test: p=0.576) | |||
none | 51 (72.9%) | 73.176 ±16.61 | 70.00 (50.00:145.0) |
univascular | 9 (12.9%) | 77.556 ±15.51 | 76.00 (55.00:110.0) |
bivascular | 5 (7.1%) | 75.000 ±14.63 | 68.00 (65.00:100.0) |
trivascular | 5 (7.1%) | 68.000 ±6.16 | 66.00 (60.00:76.0) |
Typical angina (Wilcoxon rank sum test with continuity correction: p=0.363) | |||
yes | 52 (74.3%) | 71.962 ±12.63 | 70.00 (55.00:120.0) |
no | 18 (25.7%) | 77.944 ±22.27 | 75.00 (50.00:145.0) |
Other anti-ischaemic medication (Wilcoxon rank sum test with continuity correction: p=0.478) | |||
yes | 38 (54.3%) | 72.026 ±13.04 | 70.00 (55.00:120.0) |
no | 32 (45.7%) | 75.250 ±18.47 | 75.00 (50.00:145.0) |
Nitrates (Wilcoxon rank sum test with continuity correction: p=0.637) | |||
yes | 35 (50.0%) | 72.314 ±13.53 | 70.00 (55.00:120.0) |
no | 35 (50.0%) | 74.686 ±17.76 | 72.00 (50.00:145.0) |
- De asemenea, in literatura se specifica ca prezenta BRS-ului se asociaza cu deteriorarea functiei VS dar si stucturii VS (dimensiunile VS si marimea SIV- septului interventricular)- si daca aceasta deteriorare este corelata cu largimea QRS-ului si severitatea ischemiei
IVS dissynchronism (NU) IVS size (mm) (NU) Systolic LV diameter (mm) (DA) Diastolic LV diameter (mm) (DA)
~ QRS (ms) (?), Coronary lessions (NU), Coronary lessions4 (NU)
Subset | N | Mean ±SD | Med (min:max) |
QRS (ms) (Shapiro-Wilk normality test: p<0.001) | |||
(total) | 70 (100.0%) | 134.714 ±8.96 | 130.00 (120.00:160.0) |
IVS dissynchronism (Wilcoxon rank sum test with continuity correction: p=0.414) | |||
yes | 68 (97.1%) | 134.853 ±9.06 | 130.00 (120.00:160.0) |
no | 2 (2.9%) | 130.000 ±0.00 | 130.00 (130.00:130.0) |
IVS size (mm) (Spearman's rank correlation rho: R=-0.091, p=0.452) | |||
(total) | 70 (100.0%) | 11.671 ±1.64 | 12.00 (8.00:16.0) |
Systolic LV diameter (mm) (Spearman's rank correlation rho: R=0.476, p<0.001) | |||
(total) | 70 (100.0%) | 56.486 ±9.31 | 55.50 (38.00:87.0) |
Diastolic LV diameter (mm) (Spearman's rank correlation rho: R=0.499, p<0.001) | |||
(total) | 70 (100.0%) | 41.529 ±11.53 | 40.00 (20.00:77.0) |
Variable | Details | yes | no | Total | Statistics |
Coronary lessions | 19 (27.1%) | 51 (72.9%) | 70 | ||
IVS dissynchronism | 19 (100%) | 49 (96.1%) | 68 (97.1%) | OR=1.97 [0.09, 42.91] (p>0.999) | |
IVS size (mm) | M (min:max) | 12 (9:15) | 12 (8:16) | 12 (8:16) | MW: p=0.172 |
μ ±SD | 12.11 ±1.76 | 11.51 ±1.58 | 11.67 ±1.64 | ||
Systolic LV diameter (mm) | M (min:max) | 53 (44:74) | 58 (38:87) | 55.5 (38:87) | T-test: p=0.419 |
μ ±SD | 55.00 ±9.0 | 57.04 ±9.45 | 56.49 ±9.31 | ||
Diastolic LV diameter (mm) | M (min:max) | 39 (25:61) | 40 (20:77) | 40 (20:77) | MW: p=0.731 |
μ ±SD | 40.79 ±10.9 | 41.80 ±11.8 | 41.53 ±11.5 | ||
μ ±SD = Mean (standard deviation); M (min:max) = Median (min:max); OR = odds-ratio [95% CI] and p value from Fisher test); | |||||
Variable | Details | none | univascular | bivascular | trivascular | Total | Statistics |
Coronary lessions4 | 51 (72.9%) | 9 (12.9%) | 5 (7.1%) | 5 (7.1%) | 70 | ||
IVS dissynchronism | 49 (96.1%) | 9 (100%) | 5 (100%) | 5 (100%) | 68 (97.1%) | V=0.10 (p=0.857) | |
IVS size (mm) | M (min:max) | 12 (8:16) | 12 (9:14) | 13 (11:15) | 14 (10:14) | 12 (8:16) | KW: p=0.293 |
μ ±SD | 11.51 ±1.58 | 11.56 ±1.67 | 12.80 ±1.48 | 12.40 ±2.19 | 11.67 ±1.64 | ||
Systolic LV diameter (mm) | M (min:max) | 58 (38:87) | 56 (45:74) | 51 (44:65) | 53 (50:58) | 55.5 (38:87) | KW: p=0.570 |
μ ±SD | 57.04 ±9.45 | 57.89 ±11.2 | 51.60 ±8.2 | 53.20 ±2.95 | 56.49 ±9.31 | ||
Diastolic LV diameter (mm) | M (min:max) | 40 (20:77) | 40 (25:61) | 38 (28:55) | 37 (32:40) | 40 (20:77) | KW: p=0.651 |
μ ±SD | 41.80 ±11.8 | 44.22 ±13.1 | 38.80 ±11.6 | 36.60 ±3.21 | 41.53 ±11.5 | ||
μ ±SD = Mean (standard deviation); M (min:max) = Median (min:max); OR = odds-ratio [95% CI] and p value from Fisher test); | |||||||
- Prezenta BRS-ului confirma o evolutie nefavorabila, crescand incidenta tulburarilor de ritm- deci daca exista o legatura intre BRS si Fibrilatie atriala, si daca aceasta apare mai frecvent la cei cu leziuni obstructive coronariene sau microvasculara sau la cei cu cmd.
Nu, maybe coronary lessions (OR=2, p=0.242)
Atrial fibrilation ~ Coronary lessions, Coronary lessions4, Coronarography indication: CMD
Variable | Details | yes | no | Total | Statistics |
Atrial fibrilation | 21 (30.0%) | 49 (70.0%) | 70 | ||
Coronary lessions | 8 (38.1%) | 11 (22.4%) | 19 (27.1%) | OR=2.13 [0.70, 6.43] (p=0.242) | |
Coronary lessions4 | none | 13 (61.9%) | 38 (77.6%) | 51 (72.9%) | V=0.31 (p=0.081) |
univascular | 6 (28.6%) | 3 (6.1%) | 9 (12.9%) | ||
bivascular | 1 (4.8%) | 4 (8.2%) | 5 (7.1%) | ||
trivascular | 1 (4.8%) | 4 (8.2%) | 5 (7.1%) | ||
Coronarography indication: CMD | 11 (52.4%) | 19 (38.8%) | 30 (42.9%) | OR=1.74 [0.62, 4.87] (p=0.307) | |
OR = odds-ratio [95% CI] and p value from Fisher test); | |||||
- Femeile cu brs nou aparut- au mai frecvent afectate microvasculara
Sex:F, LBBB type ~ Coronary lessions
Yes
vs. Coronary lessions | |||
LBBB type | yes | no | (total) |
new | 5 (41.7% / 71.4%) | 7 (58.3% / 25.9%) | 12 (35.3%) |
permanent | 2 (9.1% / 28.6%) | 20 (90.9% / 74.1%) | 22 (64.7%) |
(total) | 7 (20.6%) | 27 (79.4%) | 34 (100%) |
OR=7.14 [1.12, 45.52], phi=0.39 (p=0.070) | |||
- Cand este vb de cmd si brs- femeile primesc mai putin terapie de resincronizare
??? (mai jos?)
- Brs-ul are si rol prognostic, la femei BRS-ul se coreleaza cu o incidenta mai mare a insuficientei cardiace, iar la barbati brs-ul este un factor predictor pt mortalitatea prin boala coronariana (iar aceste diferente nu par a fi date de comorbiditati, ci mai degraba ca la femei apare un BRS mai adevarat decat la barbati, cu o durata chiar mai scurta a complexului decat la barbati)
- Prognosticul acestor pacienti este influentat si de varsta, fiind direct proportional cu aceasta.
ICC/IVS, NYHA ~ Sex (NU), Varsta (NU)
Variable | Details | F | M | Total | Statistics |
Sex | 35 (50.0%) | 35 (50.0%) | 70 | ||
ICC/IVS | 23 (65.7%) | 27 (77.1%) | 50 (71.4%) | OR=0.57 [0.20, 1.63] (p=0.428) | |
NYHA | II | 9 (39.1%) | 14 (51.9%) | 23 (46.0%) | OR=0.60 [0.19, 1.84] (p=0.407) |
III | 14 (60.9%) | 13 (48.1%) | 27 (54.0%) | ||
OR = odds-ratio [95% CI] and p value from Fisher test); | |||||
Subset | N | Mean ±SD | Med (min:max) |
Age (Shapiro-Wilk normality test: p=0.617) | |||
(total) | 70 (100.0%) | 67.014 ±8.89 | 67.00 (47.00:88.0) |
ICC/IVS (Welch Two Sample t-test: p=0.370) | |||
yes | 50 (71.4%) | 67.600 ±9.13 | 68.50 (47.00:87.0) |
no | 20 (28.6%) | 65.550 ±8.30 | 65.50 (50.00:88.0) |
NYHA (Welch Two Sample t-test: p=0.633) | |||
II | 23 (46.0%) | 66.913 ±9.96 | 68.00 (47.00:84.0) |
III | 27 (54.0%) | 68.185 ±8.51 | 69.00 (52.00:87.0) |
ICC/IVS, NYHA ~ Sex + Varsta + comorbiditati
Absolutely nothing
- Legat de tratament interventional: spuneam ca se pare ca femeile au supravietuire mult mai buna dupa terapia de resincronizare, insa o primesc mai putin decat barbatii
NU
CRT indication, CRT implanted ~ Sex
Variable | Details | F | M | Total | Statistics |
Sex | 35 (50.0%) | 35 (50.0%) | 70 | ||
CRT indication | 9 (25.7%) | 11 (31.4%) | 20 (28.6%) | OR=0.76 [0.27, 2.14] (p=0.792) | |
CRT implanted | 2 (5.7%) | 6 (17.1%) | 8 (11.4%) | OR=0.29 [0.05, 1.57] (p=0.259) | |
OR = odds-ratio [95% CI] and p value from Fisher test); | |||||
- De asemenea, atunci cand au leziuni coronariene, la femei sunt sanse mai mici sa primeasca stent decat la barbati
[prea putini]
- Tratamentul medicamentos, atat pt cardiomiopatia dilatativa cat si pt ischemie, este de asemenea suboptimal la femei fata de barbati: acestea primesc medicatie pt CMD: betablocanta, IECA, antialdosteronice (spironolactona) mai putin decat barbatii, iar pt ischemie primesc betablocante, IECA, antiagregante, statine mai putin si in doze mai mici decat barbatii!
Tratamente ~ Sex
Variable | Details | F | M | Total | Statistics |
Sex | 35 (50.0%) | 35 (50.0%) | 70 | ||
Age | M (min:max) | 66 (47:88) | 69 (48:87) | 67 (47:88) | T-test: p=0.137 |
μ ±SD | 65.43 ±8.51 | 68.60 ±9.1 | 67.01 ±8.89 | ||
LBBB type | new | 12 (34.3%) | 8 (22.9%) | 20 (28.6%) | V=0.18 (p=0.528) |
permanent | 22 (62.9%) | 24 (68.6%) | 46 (65.7%) | ||
intermittent | 1 (2.9%) | 2 (5.7%) | 3 (4.3%) | ||
alternating | 0 | 1 (2.9%) | 1 (1.4%) | ||
QRS (ms) | M (min:max) | 130 (120:160) | 140 (120:150) | 130 (120:160) | MW: p=0.018 |
μ ±SD | 132.57 ±9.19 | 136.86 ±8.32 | 134.71 ±8.96 | ||
Uric acid | M (min:max) | 6.32 (2.78:9.95) | 7.1 (4.64:11.45) | 6.65 (2.78:11.45) | MW: p=0.021 |
μ ±SD | 6.43 ±1.68 | 7.73 ±2.09 | 7.08 ±1.99 | ||
Heart rate | M (min:max) | 70 (55:120) | 72 (50:145) | 71 (50:145) | MW: p=0.616 |
μ ±SD | 72.80 ±14.8 | 74.20 ±16.8 | 73.50 ±15.7 | ||
SBP at admission | M (min:max) | 130 (110:190) | 130 (100:180) | 130 (100:190) | MW: p=0.797 |
μ ±SD | 132.14 ±16.7 | 133.14 ±20.0 | 132.64 ±18.3 | ||
DBP at admission | M (min:max) | 80 (60:100) | 80 (60:100) | 80 (60:100) | MW: p=0.363 |
μ ±SD | 77.43 ±12.2 | 79.29 ±10.6 | 78.36 ±11.4 | ||
Coronarography indication: angina | 31 (88.6%) | 22 (62.9%) | 53 (75.7%) | OR=4.58 [1.32, 15.93] (p=0.024) | |
Coronarography indication: CMD | 12 (34.3%) | 18 (51.4%) | 30 (42.9%) | OR=0.49 [0.19, 1.29] (p=0.227) | |
CRT indication | 9 (25.7%) | 11 (31.4%) | 20 (28.6%) | OR=0.76 [0.27, 2.14] (p=0.792) | |
CRT implanted | 2 (5.7%) | 6 (17.1%) | 8 (11.4%) | OR=0.29 [0.05, 1.57] (p=0.259) | |
Normal coronaries | 28 (80.0%) | 23 (65.7%) | 51 (72.9%) | OR=2.09 [0.71, 6.16] (p=0.282) | |
Dominant coronary | right | 28 (80.0%) | 27 (77.1%) | 55 (78.6%) | OR=1.19 [0.38, 3.72] (p>0.999) |
left | 7 (20.0%) | 8 (22.9%) | 15 (21.4%) | ||
Coronary lessions | 7 (20.0%) | 12 (34.3%) | 19 (27.1%) | OR=0.48 [0.16, 1.42] (p=0.282) | |
Coronary lessions4 | none | 28 (80.0%) | 23 (65.7%) | 51 (72.9%) | V=0.16 (p=0.596) |
univascular | 3 (8.6%) | 6 (17.1%) | 9 (12.9%) | ||
bivascular | 2 (5.7%) | 3 (8.6%) | 5 (7.1%) | ||
trivascular | 2 (5.7%) | 3 (8.6%) | 5 (7.1%) | ||
Stentation | 3 (8.6%) | 2 (5.7%) | 5 (7.1%) | OR=1.55 [0.24, 9.88] (p>0.999) | |
Coronary lessions treatment | surgery | 2 (50.0%) | 5 (50.0%) | 7 (50.0%) | OR=1.00 [0.10, 10.17] (p>0.999) |
conservative | 2 (50.0%) | 5 (50.0%) | 7 (50.0%) | ||
abord_coro | femoral | 1 (2.9%) | 4 (11.4%) | 5 (7.1%) | OR=0.23 [0.02, 2.15] (p=0.356) |
radial | 34 (97.1%) | 31 (88.6%) | 65 (92.9%) | ||
Typical angina | 30 (85.7%) | 22 (62.9%) | 52 (74.3%) | OR=3.55 [1.10, 11.41] (p=0.054) | |
Atypical pain | 4 (11.4%) | 6 (17.1%) | 10 (14.3%) | OR=0.62 [0.16, 2.44] (p=0.734) | |
Smoking | 10 (28.6%) | 34 (97.1%) | 44 (62.9%) | OR=0.01 [0.00, 0.10] (p<0.001) | |
Total cholesterol | M (min:max) | 189 (111:268) | 168 (98:260) | 173 (98:268) | T-test: p=0.194 |
μ ±SD | 182.31 ±42.6 | 168.80 ±43.6 | 175.56 ±43.3 | ||
LDL cholesterol | M (min:max) | 108 (45:168) | 90 (37:162) | 98.5 (37:168) | T-test: p=0.146 |
μ ±SD | 106.37 ±33.2 | 95.00 ±31.4 | 100.69 ±32.6 | ||
HDL cholesterol | M (min:max) | 42 (25:57) | 38 (25:69) | 40 (25:69) | MW: p=0.441 |
μ ±SD | 40.94 ±7.87 | 40.51 ±10.1 | 40.73 ±9.0 | ||
Tryglicerides | M (min:max) | 161 (60:472) | 135 (47:473) | 150.5 (47:473) | MW: p=0.121 |
μ ±SD | 168.37 ±77.0 | 145.71 ±69.3 | 157.04 ±73.6 | ||
Glicaemia (mg/dl) | M (min:max) | 109 (85:247) | 101 (82:225) | 102.5 (82:247) | MW: p=0.105 |
μ ±SD | 121.51 ±41.1 | 108.69 ±28.4 | 115.10 ±35.7 | ||
ESR | M (min:max) | 16 (4:40) | 10 (2:34) | 13 (2:40) | MW: p=0.003 |
μ ±SD | 18.57 ±9.67 | 12.26 ±8.58 | 15.41 ±9.62 | ||
TSH | M (min:max) | 1.41 (0.23:4.02) | 2.26 (0.14:3.98) | 1.71 (0.14:4.02) | MW: p=0.029 |
μ ±SD | 1.62 ±0.903 | 2.20 ±1.09 | 1.91 ±1.03 | ||
Troponin | reacted | 1 (7.7%) | 2 (18.2%) | 3 (12.5%) | OR=0.38 [0.03, 4.81] (p=0.576) |
not reacted | 12 (92.3%) | 9 (81.8%) | 21 (87.5%) | ||
NT-proBNP | 6 (17.1%) | 9 (25.7%) | 15 (21.4%) | OR=0.60 [0.19, 1.91] (p=0.561) | |
NT-proBNP (pg/ml) | M (min:max) | 2164 (300:7735) | 2071 (1107:4602) | 2071 (300:7735) | MW: p=0.955 |
μ ±SD | 2719.50 ±2674.5 | 2377.11 ±1266.5 | 2514.07 ±1871.2 | ||
LVEF % | M (min:max) | 47 (30:68) | 43 (25:55) | 45 (25:68) | MW: p=0.488 |
μ ±SD | 43.86 ±8.9 | 41.94 ±8.72 | 42.90 ±8.8 | ||
Kinetics abnormalities | 20 (57.1%) | 26 (74.3%) | 46 (65.7%) | OR=0.46 [0.17, 1.27] (p=0.208) | |
IVS dissynchronism | 33 (94.3%) | 35 (100%) | 68 (97.1%) | OR=0.19 [0.01, 4.08] (p=0.493) | |
IVS size (mm) | M (min:max) | 12 (9:15) | 11 (8:16) | 12 (8:16) | MW: p=0.287 |
μ ±SD | 11.89 ±1.62 | 11.46 ±1.65 | 11.67 ±1.64 | ||
Systolic LV diameter (mm) | M (min:max) | 52 (38:70) | 58 (40:87) | 55.5 (38:87) | T-test: p=0.014 |
μ ±SD | 53.77 ±8.0 | 59.20 ±9.83 | 56.49 ±9.31 | ||
Diastolic LV diameter (mm) | M (min:max) | 36 (23:60) | 43 (20:77) | 40 (20:77) | MW: p=0.004 |
μ ±SD | 37.91 ±10.5 | 45.14 ±11.5 | 41.53 ±11.5 | ||
Diastolic disfunction | 34 (97.1%) | 34 (97.1%) | 68 (97.1%) | OR=1.00 [0.06, 16.65] (p>0.999) | |
Diastolic disfunction4 | none | 1 (2.9%) | 1 (2.9%) | 2 (2.9%) | V=0.06 (p=0.974) |
mild | 26 (74.3%) | 25 (71.4%) | 51 (72.9%) | ||
moderate | 6 (17.1%) | 6 (17.1%) | 12 (17.1%) | ||
severe | 2 (5.7%) | 3 (8.6%) | 5 (7.1%) | ||
HBP | 31 (88.6%) | 30 (85.7%) | 61 (87.1%) | OR=1.29 [0.32, 5.28] (p>0.999) | |
HBP4 | none | 4 (11.4%) | 5 (14.3%) | 9 (12.9%) | V=0.21 (p=0.372) |
I | 1 (2.9%) | 1 (2.9%) | 2 (2.9%) | ||
II | 14 (40.0%) | 20 (57.1%) | 34 (48.6%) | ||
III | 16 (45.7%) | 9 (25.7%) | 25 (35.7%) | ||
DM | 15 (42.9%) | 10 (28.6%) | 25 (35.7%) | OR=1.87 [0.69, 5.06] (p=0.318) | |
NYHA | II | 9 (39.1%) | 14 (51.9%) | 23 (46.0%) | OR=0.60 [0.19, 1.84] (p=0.407) |
III | 14 (60.9%) | 13 (48.1%) | 27 (54.0%) | ||
Atrial fibrilation | 8 (22.9%) | 13 (37.1%) | 21 (30.0%) | OR=0.50 [0.18, 1.43] (p=0.297) | |
Obesity | 28 (80.0%) | 21 (60.0%) | 49 (70.0%) | OR=2.67 [0.92, 7.77] (p=0.117) | |
Other comorbidities | 21 (60.0%) | 21 (60.0%) | 42 (60.0%) | OR=1.00 [0.38, 2.60] (p>0.999) | |
Oral antidiabetics | 7 (20.0%) | 8 (22.9%) | 15 (21.4%) | OR=0.84 [0.27, 2.65] (p>0.999) | |
Insulin | 5 (14.3%) | 3 (8.6%) | 8 (11.4%) | OR=1.78 [0.39, 8.09] (p=0.710) | |
ICC/IVS | 23 (65.7%) | 27 (77.1%) | 50 (71.4%) | OR=0.57 [0.20, 1.63] (p=0.428) | |
Arrhythmia | 26 (74.3%) | 26 (74.3%) | 52 (74.3%) | OR=1.00 [0.34, 2.92] (p>0.999) | |
Arrhythmia type | supra-ventricular extrasystole | 6 (31.6%) | 3 (20.0%) | 9 (26.5%) | V=0.35 (p=0.235) |
ventricular extrasystole | 10 (52.6%) | 5 (33.3%) | 15 (44.1%) | ||
focal atrial tachycardia | 0 | 1 (6.7%) | 1 (2.9%) | ||
TVNS | 3 (15.8%) | 6 (40.0%) | 9 (26.5%) | ||
Antiarrhythmic medication | 8 (23.5%) | 11 (32.4%) | 19 (27.9%) | OR=0.64 [0.22, 1.87] (p=0.590) | |
Antiarrhythmic drug | amiodarona | 7 (100%) | 10 (90.9%) | 17 (94.4%) | OR=2.14 [0.08, 60.17] (p>0.999) |
propafenona | 0 | 1 (9.1%) | 1 (5.6%) | ||
Anticoagulant medication | 8 (22.9%) | 13 (38.2%) | 21 (30.4%) | OR=0.48 [0.17, 1.37] (p=0.197) | |
Antiplatelet medication | 26 (74.3%) | 20 (57.1%) | 46 (65.7%) | OR=2.17 [0.79, 5.96] (p=0.208) | |
Antiplatelet dosage | M (min:max) | 75 (75:150) | 75 (75:150) | 75 (75:150) | MW: p=0.609 |
μ ±SD | 82.69 ±20.9 | 80.00 ±17.4 | 81.52 ±19.3 | ||
Beta-blockers | 34 (97.1%) | 32 (91.4%) | 66 (94.3%) | OR=3.19 [0.32, 32.24] (p=0.614) | |
Beta-blocker | metoprolol | 16 (47.1%) | 11 (33.3%) | 27 (40.3%) | V=0.19 (p=0.473) |
bisoprolol | 12 (35.3%) | 12 (36.4%) | 24 (35.8%) | ||
nebivolol | 3 (8.8%) | 7 (21.2%) | 10 (14.9%) | ||
carvedilol | 3 (8.8%) | 3 (9.1%) | 6 (9.0%) | ||
Beta-blocker dosage | M (min:max) | 25 (2.5:100) | 5 (2.5:100) | 10 (2.5:100) | MW: p=0.315 |
μ ±SD | 42.41 ±41.6 | 33.55 ±39.5 | 38.04 ±40.5 | ||
ACE inhibitors / sartans | 33 (97.1%) | 33 (94.3%) | 66 (95.7%) | OR=2.00 [0.17, 23.14] (p>0.999) | |
ACE inhibitor | prestarium | 19 (100%) | 24 (92.3%) | 43 (95.6%) | OR=3.98 [0.18, 87.82] (p=0.501) |
ramipril | 0 | 2 (7.7%) | 2 (4.4%) | ||
Sartan | candesartan | 8 (57.1%) | 6 (85.7%) | 14 (66.7%) | V=0.35 (p=0.463) |
olmesartan | 2 (14.3%) | 1 (14.3%) | 3 (14.3%) | ||
telminsartan | 2 (14.3%) | 0 | 2 (9.5%) | ||
valsartan | 2 (14.3%) | 0 | 2 (9.5%) | ||
ACE inhibitor dosage | M (min:max) | 5 (2.5:10) | 5 (2.5:10) | 5 (2.5:10) | MW: p=0.640 |
μ ±SD | 5.87 ±2.27 | 6.25 ±2.67 | 6.09 ±2.49 | ||
Sartan dosage | M (min:max) | 26 (8:160) | 16 (8:40) | 26 (8:160) | MW: p=0.342 |
μ ±SD | 36.86 ±39.9 | 20.57 ±13.7 | 31.43 ±34.0 | ||
Statins | 26 (74.3%) | 28 (80.0%) | 54 (77.1%) | OR=0.72 [0.24, 2.22] (p=0.777) | |
Statin | atorvastatina | 19 (73.1%) | 21 (75.0%) | 40 (74.1%) | V=0.14 (p=0.576) |
rosuvastatina | 7 (26.9%) | 6 (21.4%) | 13 (24.1%) | ||
simvastatina | 0 | 1 (3.6%) | 1 (1.9%) | ||
Statin dosage | M (min:max) | 10 (5:40) | 20 (10:40) | 15 (5:40) | MW: p=0.344 |
μ ±SD | 15.19 ±7.28 | 18.21 ±10.2 | 16.76 ±8.96 | ||
Diuretics | 26 (74.3%) | 28 (80.0%) | 54 (77.1%) | OR=0.72 [0.24, 2.22] (p=0.777) | |
Diuretic | ansa | 4 (15.4%) | 2 (6.9%) | 6 (10.9%) | V=0.15 (p=0.519) |
ansa/economisitorK | 17 (65.4%) | 19 (65.5%) | 36 (65.5%) | ||
tiazidic | 5 (19.2%) | 8 (27.6%) | 13 (23.6%) | ||
Other anti-ischaemic medication | 23 (65.7%) | 15 (42.9%) | 38 (54.3%) | OR=2.56 [0.97, 6.72] (p=0.092) | |
Nitrates | 21 (60.0%) | 14 (40.0%) | 35 (50.0%) | OR=2.25 [0.86, 5.85] (p=0.151) | |
Trimetazidine | 4 (11.4%) | 1 (2.9%) | 5 (7.1%) | OR=4.39 [0.46, 41.40] (p=0.356) | |
Ca channel blockers | 15 (42.9%) | 10 (28.6%) | 25 (35.7%) | OR=1.87 [0.69, 5.06] (p=0.318) | |
Digoxin | 6 (17.1%) | 6 (17.1%) | 12 (17.1%) | OR=1.00 [0.29, 3.47] (p>0.999) | |
μ ±SD = Mean (standard deviation); M (min:max) = Median (min:max); MW = Mann-Whitney Test; Welch = Welch T-Test (not assuming equal variances); OR/RR = odds-ratio / risk-ratio [95% CI] and p value from Fisher test); V = Cramér V (p value from Chi² test); | |||||
- Tratamentul medicamentos in angina microvaculara (adica coronare normale) ar trebui sa fie mult mai intens si sa cuprinda betablocante, antiagregante, statine, blocante de calciu si alte antiischemice, fiind foarte greu de controlat simptomatologia, insa pana in momentul de fata nu se stie exact care este diferenta doar pt angina microvasculara si cea macrovasculara in privinta tratamentului la femei vs barbati
Coronary lessions: Tratamente ~ Sex
Variable | Details | F | M | Total | Statistics |
Sex | 7 (36.8%) | 12 (63.2%) | 19 | ||
Age | M (min:max) | 70 (58:76) | 70 (64:84) | 70 (58:84) | T-test: p=0.322 |
μ ±SD | 68.71 ±5.74 | 71.50 ±5.74 | 70.47 ±5.75 | ||
LBBB type | new | 5 (71.4%) | 1 (8.3%) | 6 (31.6%) | V=0.66 (p=0.016) |
permanent | 2 (28.6%) | 10 (83.3%) | 12 (63.2%) | ||
intermittent | 0 | 1 (8.3%) | 1 (5.3%) | ||
alternating | 0 | 0 | 0 | ||
QRS (ms) | M (min:max) | 130 (130:150) | 130 (120:140) | 130 (120:150) | MW: p>0.999 |
μ ±SD | 134.29 ±7.87 | 133.33 ±6.51 | 133.68 ±6.84 | ||
Uric acid | M (min:max) | 6.21 (4.67:9.7) | 8.02 (4.99:11.2) | 7.09 (4.67:11.2) | MW: p=0.352 |
μ ±SD | 6.95 ±1.75 | 8.09 ±2.4 | 7.67 ±2.21 | ||
Heart rate | M (min:max) | 70 (60:110) | 74 (55:100) | 72 (55:110) | MW: p=0.799 |
μ ±SD | 74.57 ±16.4 | 74.25 ±12.1 | 74.37 ±13.4 | ||
SBP at admission | M (min:max) | 120 (120:160) | 140 (100:180) | 130 (100:180) | T-test: p=0.464 |
μ ±SD | 131.43 ±16.8 | 138.75 ±22.4 | 136.05 ±20.3 | ||
DBP at admission | M (min:max) | 80 (70:90) | 80 (60:100) | 80 (60:100) | T-test: p=0.440 |
μ ±SD | 77.14 ±7.56 | 80.83 ±10.8 | 79.47 ±9.7 | ||
Coronarography indication: angina | 7 (100%) | 11 (91.7%) | 18 (94.7%) | OR=1.96 [0.07, 54.67] (p>0.999) | |
Coronarography indication: CMD | 1 (14.3%) | 2 (16.7%) | 3 (15.8%) | OR=0.83 [0.06, 11.28] (p>0.999) | |
CRT indication | 1 (14.3%) | 2 (16.7%) | 3 (15.8%) | OR=0.83 [0.06, 11.28] (p>0.999) | |
CRT implanted | 1 (14.3%) | 1 (8.3%) | 2 (10.5%) | OR=1.83 [0.10, 34.85] (p>0.999) | |
Normal coronaries | 0 | 0 | 0 | OR=1.67 [0.03, 93.12] (p>0.999) | |
Dominant coronary | right | 7 (100%) | 10 (83.3%) | 17 (89.5%) | OR=3.57 [0.15, 85.68] (p=0.509) |
left | 0 | 2 (16.7%) | 2 (10.5%) | ||
Coronary lessions | 7 (100%) | 12 (100%) | 19 (100%) | OR=0.60 [0.01, 33.52] (p>0.999) | |
Coronary lessions4 | none | 0 | 0 | 0 | V=0.07 (p=0.956) |
univascular | 3 (42.9%) | 6 (50.0%) | 9 (47.4%) | ||
bivascular | 2 (28.6%) | 3 (25.0%) | 5 (26.3%) | ||
trivascular | 2 (28.6%) | 3 (25.0%) | 5 (26.3%) | ||
Stentation | 3 (42.9%) | 2 (16.7%) | 5 (26.3%) | OR=3.75 [0.44, 31.62] (p=0.305) | |
Coronary lessions treatment | surgery | 2 (50.0%) | 5 (50.0%) | 7 (50.0%) | OR=1.00 [0.10, 10.17] (p>0.999) |
conservative | 2 (50.0%) | 5 (50.0%) | 7 (50.0%) | ||
abord_coro | femoral | 0 | 2 (16.7%) | 2 (10.5%) | OR=0.28 [0.01, 6.72] (p=0.509) |
radial | 7 (100%) | 10 (83.3%) | 17 (89.5%) | ||
Typical angina | 6 (85.7%) | 11 (91.7%) | 17 (89.5%) | OR=0.55 [0.03, 10.37] (p>0.999) | |
Atypical pain | 1 (14.3%) | 1 (8.3%) | 2 (10.5%) | OR=1.83 [0.10, 34.85] (p>0.999) | |
Smoking | 1 (14.3%) | 12 (100%) | 13 (68.4%) | OR=0.01 [0.00, 0.26] (p<0.001) | |
Total cholesterol | M (min:max) | 194 (124:240) | 177 (99:260) | 185 (99:260) | T-test: p=0.915 |
μ ±SD | 185.14 ±39.7 | 182.83 ±47.1 | 183.68 ±43.4 | ||
LDL cholesterol | M (min:max) | 113 (64:168) | 105.5 (53:162) | 109 (53:168) | T-test: p=0.936 |
μ ±SD | 110.29 ±33.2 | 108.92 ±36.0 | 109.42 ±34.1 | ||
HDL cholesterol | M (min:max) | 39 (28:50) | 36 (29:52) | 38 (28:52) | T-test: p=0.830 |
μ ±SD | 38.29 ±7.41 | 37.50 ±7.65 | 37.79 ±7.36 | ||
Tryglicerides | M (min:max) | 187 (95:287) | 162 (84:473) | 168 (84:473) | MW: p=0.650 |
μ ±SD | 177.71 ±74.0 | 178.50 ±99.9 | 178.21 ±89.0 | ||
Glicaemia (mg/dl) | M (min:max) | 115 (90:168) | 101.5 (83:225) | 102 (83:225) | MW: p=0.352 |
μ ±SD | 120.14 ±27.5 | 111.17 ±37.1 | 114.47 ±33.4 | ||
ESR | M (min:max) | 26 (10:40) | 12 (4:30) | 13 (4:40) | MW: p=0.008 |
μ ±SD | 28.43 ±10.2 | 12.75 ±7.83 | 18.53 ±11.5 | ||
TSH | M (min:max) | 1.32 (0.64:2.69) | 2.08 (0.99:3.28) | 1.65 (0.64:3.28) | MW: p=0.220 |
μ ±SD | 1.58 ±0.705 | 2.10 ±0.853 | 1.91 ±0.822 | ||
Troponin | reacted | 0 | 1 (25.0%) | 1 (10.0%) | OR=0.18 [0.01, 5.68] (p=0.400) |
not reacted | 6 (100%) | 3 (75.0%) | 9 (90.0%) | ||
NT-proBNP | 1 (14.3%) | 1 (8.3%) | 2 (10.5%) | OR=1.83 [0.10, 34.85] (p>0.999) | |
NT-proBNP (pg/ml) | M (min:max) | 2648 (2648:2648) | 1206 (1206:1206) | 1927 (1206:2648) | MW: p>0.999 |
μ ±SD | 2648.00 ±NA | 1206.00 ±NA | 1927.00 ±1019.6 | ||
LVEF % | M (min:max) | 45 (30:68) | 45 (35:55) | 45 (30:68) | T-test: p=0.774 |
μ ±SD | 46.14 ±11.9 | 44.83 ±7.77 | 45.32 ±9.18 | ||
Kinetics abnormalities | 5 (71.4%) | 11 (91.7%) | 16 (84.2%) | OR=0.23 [0.02, 3.13] (p=0.523) | |
IVS dissynchronism | 7 (100%) | 12 (100%) | 19 (100%) | OR=0.60 [0.01, 33.52] (p>0.999) | |
IVS size (mm) | M (min:max) | 14 (11:15) | 11.5 (9:14) | 12 (9:15) | T-test: p=0.021 |
μ ±SD | 13.29 ±1.38 | 11.42 ±1.62 | 12.11 ±1.76 | ||
Systolic LV diameter (mm) | M (min:max) | 50 (44:70) | 54 (45:74) | 53 (44:74) | MW: p=0.204 |
μ ±SD | 52.00 ±9.07 | 56.75 ±8.86 | 55.00 ±9.0 | ||
Diastolic LV diameter (mm) | M (min:max) | 32 (25:60) | 40 (35:61) | 39 (25:61) | MW: p=0.075 |
μ ±SD | 35.86 ±12.0 | 43.67 ±9.66 | 40.79 ±10.9 | ||
Diastolic disfunction | 7 (100%) | 12 (100%) | 19 (100%) | OR=0.60 [0.01, 33.52] (p>0.999) | |
Diastolic disfunction4 | none | 0 | 0 | 0 | V=0.39 (p=0.236) |
mild | 6 (85.7%) | 10 (83.3%) | 16 (84.2%) | ||
moderate | 0 | 2 (16.7%) | 2 (10.5%) | ||
severe | 1 (14.3%) | 0 | 1 (5.3%) | ||
HBP | 6 (85.7%) | 12 (100%) | 18 (94.7%) | OR=0.17 [0.01, 4.88] (p=0.368) | |
HBP4 | none | 1 (14.3%) | 0 | 1 (5.3%) | V=0.50 (p=0.191) |
I | 0 | 1 (8.3%) | 1 (5.3%) | ||
II | 2 (28.6%) | 8 (66.7%) | 10 (52.6%) | ||
III | 4 (57.1%) | 3 (25.0%) | 7 (36.8%) | ||
DM | 4 (57.1%) | 5 (41.7%) | 9 (47.4%) | OR=1.87 [0.28, 12.31] (p=0.650) | |
NYHA | II | 2 (40.0%) | 5 (71.4%) | 7 (58.3%) | OR=0.27 [0.02, 3.02] (p=0.558) |
III | 3 (60.0%) | 2 (28.6%) | 5 (41.7%) | ||
Atrial fibrilation | 3 (42.9%) | 5 (41.7%) | 8 (42.1%) | OR=1.05 [0.16, 6.92] (p>0.999) | |
Obesity | 5 (71.4%) | 7 (58.3%) | 12 (63.2%) | OR=1.79 [0.24, 13.21] (p=0.656) | |
Other comorbidities | 3 (42.9%) | 6 (50.0%) | 9 (47.4%) | OR=0.75 [0.11, 4.90] (p>0.999) | |
Oral antidiabetics | 2 (28.6%) | 3 (25.0%) | 5 (26.3%) | OR=1.20 [0.15, 9.77] (p>0.999) | |
Insulin | 2 (28.6%) | 2 (16.7%) | 4 (21.1%) | OR=2.00 [0.21, 18.69] (p=0.603) | |
ICC/IVS | 5 (71.4%) | 7 (58.3%) | 12 (63.2%) | OR=1.79 [0.24, 13.21] (p=0.656) | |
Arrhythmia | 6 (85.7%) | 8 (66.7%) | 14 (73.7%) | OR=3.00 [0.26, 34.20] (p=0.603) | |
Arrhythmia type | supra-ventricular extrasystole | 2 (50.0%) | 1 (25.0%) | 3 (37.5%) | V=0.41 (p=0.513) |
ventricular extrasystole | 2 (50.0%) | 2 (50.0%) | 4 (50.0%) | ||
focal atrial tachycardia | 0 | 0 | 0 | ||
TVNS | 0 | 1 (25.0%) | 1 (12.5%) | ||
Antiarrhythmic medication | 1 (14.3%) | 1 (8.3%) | 2 (10.5%) | OR=1.83 [0.10, 34.85] (p>0.999) | |
Antiarrhythmic drug | amiodarona | 1 (100%) | 1 (100%) | 2 (100%) | OR=1.00 [0.01, 92.42] (p>0.999) |
propafenona | 0 | 0 | 0 | ||
Anticoagulant medication | 3 (42.9%) | 5 (45.5%) | 8 (44.4%) | OR=0.90 [0.13, 6.08] (p>0.999) | |
Antiplatelet medication | 6 (85.7%) | 9 (75.0%) | 15 (78.9%) | OR=2.00 [0.17, 24.07] (p>0.999) | |
Antiplatelet dosage | M (min:max) | 100 (75:150) | 75 (75:150) | 75 (75:150) | MW: p=0.123 |
μ ±SD | 108.33 ±34.2 | 86.11 ±25.3 | 95.00 ±30.2 | ||
Beta-blockers | 7 (100%) | 10 (83.3%) | 17 (89.5%) | OR=3.57 [0.15, 85.68] (p=0.509) | |
Beta-blocker | metoprolol | 6 (85.7%) | 3 (30.0%) | 9 (52.9%) | V=0.55 (p=0.074) |
bisoprolol | 1 (14.3%) | 6 (60.0%) | 7 (41.2%) | ||
nebivolol | 0 | 1 (10.0%) | 1 (5.9%) | ||
carvedilol | 0 | 0 | 0 | ||
Beta-blocker dosage | M (min:max) | 100 (10:100) | 5 (2.5:100) | 25 (2.5:100) | MW: p=0.051 |
μ ±SD | 69.29 ±40.0 | 33.75 ±45.8 | 48.38 ±45.9 | ||
ACE inhibitors / sartans | 7 (100%) | 12 (100%) | 19 (100%) | OR=0.60 [0.01, 33.52] (p>0.999) | |
ACE inhibitor | prestarium | 4 (100%) | 7 (87.5%) | 11 (91.7%) | OR=1.80 [0.06, 54.33] (p>0.999) |
ramipril | 0 | 1 (12.5%) | 1 (8.3%) | ||
Sartan | candesartan | 2 (66.7%) | 3 (75.0%) | 5 (71.4%) | V=0.55 (p=0.350) |
olmesartan | 0 | 1 (25.0%) | 1 (14.3%) | ||
telminsartan | 1 (33.3%) | 0 | 1 (14.3%) | ||
valsartan | 0 | 0 | 0 | ||
ACE inhibitor dosage | M (min:max) | 7.5 (5:10) | 5 (2.5:10) | 5 (2.5:10) | MW: p=0.185 |
μ ±SD | 7.50 ±2.89 | 5.31 ±2.09 | 6.04 ±2.49 | ||
Sartan dosage | M (min:max) | 16 (8:80) | 32 (8:40) | 32 (8:80) | T-test: p=0.761 |
μ ±SD | 34.67 ±39.5 | 28.00 ±13.9 | 30.86 ±25.1 | ||
Statins | 6 (85.7%) | 11 (91.7%) | 17 (89.5%) | OR=0.55 [0.03, 10.37] (p>0.999) | |
Statin | atorvastatina | 5 (83.3%) | 10 (90.9%) | 15 (88.2%) | V=0.11 (p=0.643) |
rosuvastatina | 1 (16.7%) | 1 (9.1%) | 2 (11.8%) | ||
simvastatina | 0 | 0 | 0 | ||
Statin dosage | M (min:max) | 15 (10:40) | 20 (10:40) | 20 (10:40) | MW: p=0.421 |
μ ±SD | 18.33 ±11.7 | 22.73 ±11.9 | 21.18 ±11.7 | ||
Diuretics | 5 (71.4%) | 8 (66.7%) | 13 (68.4%) | OR=1.25 [0.16, 9.54] (p>0.999) | |
Diuretic | ansa | 1 (20.0%) | 0 | 1 (7.7%) | V=0.38 (p=0.385) |
ansa/economisitorK | 3 (60.0%) | 5 (62.5%) | 8 (61.5%) | ||
tiazidic | 1 (20.0%) | 3 (37.5%) | 4 (30.8%) | ||
Other anti-ischaemic medication | 6 (85.7%) | 9 (75.0%) | 15 (78.9%) | OR=2.00 [0.17, 24.07] (p>0.999) | |
Nitrates | 6 (85.7%) | 8 (66.7%) | 14 (73.7%) | OR=3.00 [0.26, 34.20] (p=0.603) | |
Trimetazidine | 0 | 1 (8.3%) | 1 (5.3%) | OR=0.51 [0.02, 14.28] (p>0.999) | |
Ca channel blockers | 4 (57.1%) | 8 (66.7%) | 12 (63.2%) | OR=0.67 [0.10, 4.54] (p>0.999) | |
Digoxin | 2 (28.6%) | 1 (8.3%) | 3 (15.8%) | OR=4.40 [0.32, 60.61] (p=0.523) | |
μ ±SD = Mean (standard deviation); M (min:max) = Median (min:max); MW = Mann-Whitney Test; Welch = Welch T-Test (not assuming equal variances); OR/RR = odds-ratio / risk-ratio [95% CI] and p value from Fisher test); V = Cramér V (p value from Chi² test); | |||||
1 References
- R Core Team (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/.